Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C6H13NO2 |
Molecular Weight | 131.1729 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)C[C@H](N)C(O)=O
InChI
InChIKey=ROHFNLRQFUQHCH-YFKPBYRVSA-N
InChI=1S/C6H13NO2/c1-4(2)3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/t5-/m0/s1
Molecular Formula | C6H13NO2 |
Molecular Weight | 131.1729 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Leucine is an α-amino acid used in the biosynthesis of proteins. Leucine is an essential hydrophobic amino acid. It is used in the Leucine may be used some people as a supplement to build muscle. Leucine is also found in fish, meat, and poultry. In the pharmaceutical industry, L-leucine is used for parenteral and enteral nutrition and feeding, and is also used as a flavoring product and tablet lubricant in manufacturing. Leucine is an mTOR activator. It is a dietary amino acid with the capacity to directly stimulate muscle protein synthesis. As a dietary supplement, leucine has been found to slow the degradation of muscle tissue by increasing the synthesis of muscle proteins in aged rats. Long-term leucine supplementation does not increase muscle mass or strength in healthy elderly men. Leucine potently activates the mammalian target of rapamycin kinase that regulates cell growth. Infusion of leucine into the rat brain has been shown to decrease food intake and body weight via activation of the mTOR pathway.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2221341 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28237591 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | FREAMINE III 10% Approved UseParenteral nutrition with 8.5% FreAmine® III (Amino Acid Injection) with Electrolytes is
indicated to prevent nitrogen loss or treat negative nitrogen balance in adults and pediatric
patients, where (1) the alimentary tract, by the oral, gastrostomy, or jejunostomy route, cannot or
should not be used, or adequate protein intake is not feasible by these routes; (2) gastrointestinal
absorption of protein is impaired; or (3) protein requirements are substantially increased as with
extensive burns. Dosage, route of administration, and concomitant infusion of non-protein
calories are dependent on various factors, such as nutritional metabolic status of the patient, anticipated duration of parenteral nutritional support, and vein tolerance Launch Date1971 |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
15.9 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26119505/ |
100 mg/kg single, oral dose: 100 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
LEUCINE plasma | Canis lupus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
48.63 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26119505/ |
100 mg/kg single, oral dose: 100 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
LEUCINE plasma | Canis lupus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.49 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26119505/ |
100 mg/kg single, oral dose: 100 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
LEUCINE plasma | Canis lupus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
PubMed
Title | Date | PubMed |
---|---|---|
Prevalence of mutations causing retinitis pigmentosa and other inherited retinopathies. | 2001 |
|
Expression pattern and gene characterization of asporin. a newly discovered member of the leucine-rich repeat protein family. | 2001 Apr 13 |
|
The biosynthetic incorporation of the intact leucine skeleton into sterol by the trypanosomatid Leishmania mexicana. | 2001 Apr 13 |
|
Stem cell factor presentation to c-Kit. Identification of a basolateral targeting domain. | 2001 Apr 20 |
|
Different usage of the glycosaminoglycan attachment sites of biglycan. | 2001 Apr 20 |
|
Identification of a new Leu354Pro mutation responsible for factor XIII deficiency. | 2001 Feb |
|
Determination of binding constant of transcription factor AP-1 and DNA. Application of inhibitors. | 2001 Feb |
|
The Drosophila homolog of human AF10/AF17 leukemia fusion genes (Dalf) encodes a zinc finger/leucine zipper nuclear protein required in the nervous system for maintaining EVE expression and normal growth. | 2001 Feb |
|
Homeodomain leucine zipper proteins bind to the phosphate response domain of the soybean VspB tripartite promoter. | 2001 Feb |
|
Temperature dependence of the folding and unfolding kinetics of the GCN4 leucine zipper via 13C(alpha)-NMR. | 2001 Feb |
|
A compound heterozygous one amino-acid insertion/nonsense mutation in the plectin gene causes epidermolysis bullosa simplex with plectin deficiency. | 2001 Feb |
|
The digestion rate of protein is an independent regulating factor of postprandial protein retention. | 2001 Feb |
|
Amino acid interconversions in the fetal-placental unit: the animal model and human studies in vivo. | 2001 Feb |
|
Increased albumin and fibrinogen synthesis in hemodialysis patients with normal nutritional status. | 2001 Feb |
|
Differential insulin sensitivities of glucose, amino acid, and albumin metabolism in elderly men and women. | 2001 Feb |
|
A novel syndrome affecting multiple mitochondrial functions, located by microcell-mediated transfer to chromosome 2p14-2p13. | 2001 Feb |
|
Abnormal secretion and function of recombinant human factor VII as the result of modification to a calcium binding site caused by a 15-base pair insertion in the F7 gene. | 2001 Feb 15 |
|
Multiple zonal projections of the basilar pontine nuclei to the cerebellar cortex of the rat. | 2001 Feb 19 |
|
Identification of the main ubiquitination site in human erythroid alpha-spectrin. | 2001 Feb 2 |
|
Fragmentary form of thermostable leucine dehydrogenase of Bacillus stearothermophilus: its construction and reconstitution of active fragmentary enzyme. | 2001 Feb 2 |
|
The metabolic evidence of synergistic effect between ohmefentanyl and [D-Pen2, D-Pen5] enkephalin on differentiated SH-SY5Y cells in humans. | 2001 Feb 9 |
|
Identification and characterization of a novel gene that is upregulated in leukaemia cells by nitric oxide. | 2001 Jan |
|
V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression. | 2001 Jan |
|
Precursor supply for polyketide biosynthesis: the role of crotonyl-CoA reductase. | 2001 Jan |
|
Simvastatin inhibits noradrenaline-induced hypertrophy of cultured neonatal rat cardiomyocytes. | 2001 Jan |
|
Enhanced flavour formation by combination of selected lactococci from industrial and artisanal origin with focus on completion of a metabolic pathway. | 2001 Jan |
|
Net amino acid flux across the fetal liver and placenta during spontaneous ovine parturition. | 2001 Jan |
|
Proteoglycan synthesis is increased in cells with impaired clathrin-dependent endocytosis. | 2001 Jan |
|
Characterization of 3-[(123)I]iodo-L-alpha-methyl tyrosine transport in astrocytes of neonatal rats. | 2001 Jan |
|
Effect of elective abdominal surgery on human colon protein synthesis in situ. | 2001 Jan |
|
Structure of the human zinc finger protein HIVEP3: molecular cloning, expression, exon-intron structure, and comparison with paralogous genes HIVEP1 and HIVEP2. | 2001 Jan 1 |
|
Central neurocytomas express photoreceptor differentiation. | 2001 Jan 1 |
|
Chloramine-T in radiolabeling techniques. IV. Penta-O-acetyl-N-chloro-N-methylglucamine as an oxidizing agent in radiolabelling techniques. | 2001 Jan 1 |
|
Nrf2-dependent activation of the antioxidant responsive element by tert-butylhydroquinone is independent of oxidative stress in IMR-32 human neuroblastoma cells. | 2001 Jan 12 |
|
Spontaneous dimerization and leucine-zipper induced activation of the recombinant catalytic domain of a new adenylyl cyclase of Trypanosoma brucei, GRESAG4.4B. | 2001 Jan 15 |
|
The basal turnover of yeast branched-chain amino acid permease Bap2p requires its C-terminal tail. | 2001 Jan 15 |
|
Secondary structure and post-translational modifications of the leucine-rich repeat protein PGIP (polygalacturonase-inhibiting protein) from Phaseolus vulgaris. | 2001 Jan 16 |
|
Amino acid residues in ribonuclease MC1 from bitter gourd seeds which are essential for uridine specificity. | 2001 Jan 16 |
|
Peptide models of the helical hydrophobic transmembrane segments of membrane proteins: interactions of acetyl-K2-(LA)12-K2-amide with phosphatidylethanolamine bilayer membranes. | 2001 Jan 16 |
|
Strain is more important than electrostatic interaction in controlling the pKa of the catalytic group in aspartate aminotransferase. | 2001 Jan 16 |
|
Substituting leucine for alanine-86 in the tether region of the iron-sulfur protein of the cytochrome bc1 complex affects the mobility of the [2Fe2S] domain. | 2001 Jan 16 |
|
Identification and characterization of functional domains in a mixed lineage kinase LZK. | 2001 Jan 19 |
|
PIST: a novel PDZ/coiled-coil domain binding partner for the rho-family GTPase TC10. | 2001 Jan 19 |
|
Overexpression of 12-lipoxygenase causes cardiac fibroblast cell growth. | 2001 Jan 19 |
|
Hepatitis B virus X protein activates transcription by bypassing CREB phosphorylation, not by stabilizing bZIP-DNA complexes. | 2001 Jan 23 |
|
MgATP-Bound and nucleotide-free structures of a nitrogenase protein complex between the Leu 127 Delta-Fe-protein and the MoFe-protein. | 2001 Jan 23 |
|
The bZIP-like motif of hnRNP C directs the nuclear accumulation of pre-mRNA and lethality in yeast. | 2001 Jan 26 |
|
An antiparallel four-helix bundle orients the high-affinity RNA binding sites in hnRNP C: a mechanism for RNA chaperonin activity. | 2001 Jan 26 |
|
Contryphans from Conus textile venom ducts. | 2001 Jun |
|
Cohesin-dockerin interaction in cellulosome assembly: a single hydroxyl group of a dockerin domain distinguishes between nonrecognition and high affinity recognition. | 2001 Mar 30 |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28089725
Primary cultures of peripheral blood mononuclear cells were rinsed with PBS and harvested in phosphate buffer pH 7.4 (50 mmol/L KH2PO4, 1 mmol/L EGTA, 150 mmol/L sucrose). The reaction was started by the addition of a lucigenin mixture 5 μmol/L) and NADPH (100 μmol/L) (Sigma-Aldrich) to the protein sample in a final volume of 250 μL. Branched-chain amino acids were prepared as a mixture of leucine, isoleucine and valine at 0.2–12 mmol/L Cells were exposed to increasing concentrations of BCAA (4–12 mmol/L) for 1 h Chemiluminescence was determined every 2.4 s for 3 min in a microtiter plate luminometer (Enspire Perkin Elmer). Basal activity in the absence of NADPH was subtracted from each reading and normalized to protein concentration.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 15:50:08 GMT 2023
by
admin
on
Sat Dec 16 15:50:08 GMT 2023
|
Record UNII |
GMW67QNF9C
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
53154-1
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
15131-6
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
NCI_THESAURUS |
C68442
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
47683-8
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
75268-3
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
2562-7
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
53152-5
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
47680-4
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
29293-8
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
47681-2
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
22693-6
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
57994-6
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
DSLD |
2188 (Number of products:87)
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
57996-1
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
32783-3
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
2561-9
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
72899-8
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
47682-0
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
49834-5
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
2559-3
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
21056-7
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
DSLD |
173 (Number of products:424)
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
47685-3
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
20649-0
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
53393-5
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
21057-5
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
44334-1
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
30053-3
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
47679-6
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
CFR |
21 CFR 172.320
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
2560-1
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
13403-1
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
45214-4
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
29284-7
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
32253-7
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
FDA ORPHAN DRUG |
33588
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
DSLD |
2315 (Number of products:2347)
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
25942-4
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
56954-1
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
53153-3
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
17074-6
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
25460-7
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
13768-7
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
22719-9
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
25941-6
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
2558-5
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
JECFA EVALUATION |
1423
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
53397-6
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
26710-4
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
FDA ORPHAN DRUG |
93095
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
27323-5
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
9412-8
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
32254-5
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
55933-6
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
57995-3
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
15138-1
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
||
|
LOINC |
47684-6
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
LEUCINE
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
PRIMARY | |||
|
100000092265
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
PRIMARY | |||
|
1357001
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
PRIMARY | |||
|
SUB21983
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
PRIMARY | |||
|
25017
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
PRIMARY | |||
|
SUB08446MIG
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
PRIMARY | |||
|
m6773
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
PRIMARY | Merck Index | ||
|
57427
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
PRIMARY | |||
|
7799
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
PRIMARY | |||
|
200-522-0
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
PRIMARY | |||
|
DB00149
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
PRIMARY | |||
|
523
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
PRIMARY | |||
|
D007930
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
PRIMARY | |||
|
15603
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
PRIMARY | |||
|
DTXSID9023203
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
PRIMARY | |||
|
6165
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
PRIMARY | |||
|
1557
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
PRIMARY | |||
|
6106
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
PRIMARY | |||
|
6308
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
PRIMARY | RxNorm | ||
|
CHEMBL291962
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
PRIMARY | |||
|
GMW67QNF9C
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
PRIMARY | |||
|
30006
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
PRIMARY | |||
|
GMW67QNF9C
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
PRIMARY | |||
|
1413
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
PRIMARY | |||
|
46709
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
PRIMARY | |||
|
61-90-5
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
PRIMARY | |||
|
308
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
PRIMARY | |||
|
C29599
Created by
admin on Sat Dec 16 15:50:10 GMT 2023 , Edited by admin on Sat Dec 16 15:50:10 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
impurity A at 570 nm: maximum 0.8 per cent
CHROMATOGRAPHIC PURITY (TLC)
EP
|
||
|
PARENT -> IMPURITY |
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (TLC)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (TLC)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (TLC)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (TLC)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (TLC)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |